Callan Family Office LLC Has $1.33 Million Stake in IDEXX Laboratories, Inc. $IDXX

Key Points

• Callan Family Office LLC increased its stake in IDEXX Laboratories, Inc. by 354.5% during the second quarter, now holding shares worth $1.33 million.
• Insider trading activity includes EVP Sharon E. Underberg and Nimrata Hunt, who sold thousands of shares recently, leading to notable decreases in their respective positions.
• IDEXX Laboratories reported a 10.6% year-over-year revenue increase with quarterly earnings of $3.63 per share, surpassing analysts' estimates by $0.35.

Callan Family Office LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 354.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,486 shares of the company's stock after buying an additional 1,939 shares during the period. Callan Family Office LLC's holdings in IDEXX Laboratories were worth $1,333,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $29,000. MorganRosel Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $26,000. Ameritas Advisory Services LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $36,000. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after buying an additional 30 shares during the last quarter. Finally, WPG Advisers LLC acquired a new stake in IDEXX Laboratories during the 1st quarter worth approximately $37,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 7,143 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $630.43, for a total value of $4,503,161.49. Following the completion of the transaction, the executive vice president owned 18,007 shares in the company, valued at approximately $11,352,153.01. The trade was a 28.40% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 54,057 shares of company stock worth $34,293,468. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $616.15 on Monday. The stock's fifty day moving average price is $641.49 and its two-hundred day moving average price is $543.56. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a market cap of $49.29 billion, a PE ratio of 51.30, a price-to-earnings-growth ratio of 3.99 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported $3.63 EPS for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the company earned $2.44 EPS. The company's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research reports. BTIG Research lifted their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. Morgan Stanley lifted their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a report on Friday, August 15th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They set a "buy" rating and a $625.00 price target for the company. UBS Group initiated coverage on IDEXX Laboratories in a report on Wednesday, October 1st. They set a "neutral" rating and a $720.00 price target for the company. Finally, Wall Street Zen cut IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Sunday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $656.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.